Wuhan National Pharmaceutical Technology Co.Ltd(600421) 5 announced on May 23 that the company received the annual report regulatory inquiry letter issued by Shanghai Stock Exchange on the same day, and was asked three questions including customers. The inquiry letter requires the company to supplement and disclose: whether the specific business model of mold and die platform business is reasonable in combination with the industry situation; The names of the top five customers and their related relationships, the starting time of cooperation, the sales amount and proportion, the names of the top five suppliers, the purchase amount and proportion, and the reasons for the changes in the structure of customers and suppliers in detail; Specific reasons for the sharp decline of mold and platform business during the reporting period.
At the same time, the inquiry letter also pointed out that in 2021, the company realized an income of 130 million yuan, and the total amount of operating income deduction items was 5.9988 million yuan, mainly including mold processing and waste disposal. After deducting other income unrelated to the main business or without commercial substance, the operating income was 124 million yuan. The sales of the company’s top five customers were 22.576 million yuan, accounting for 17.32% of the total annual sales, of which the sales of related parties among the top five customers were 101812 million yuan, accounting for 7.81% of the total annual sales. The Shanghai stock exchange requires the company to disclose the basic information of the above items corresponding to the deducted income, including but not limited to the business model, main agreement terms, deduction reasons and basis, etc; Explain whether it has real business background and commercial rationality; It also explains whether the sales price is fair by comparing the gross profit margin with that of non related parties.
